During the past decade, Retina-Vitreous Associates conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 3 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina-Vitreous Associates" #1 sponsor was "Kodiak Sciences Inc" with 4 trials, followed by "Johns Hopkins University" with 2 trials sponsored, "OccuLogix" with 2 trials sponsored, "Aerie Pharmaceuticals" with 1 trials sponsored and "Gemini Therapeutics, Inc." with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina-Vitreous Associates" #1 collaborator was "Genentech, Inc." with 1 trials as a collaborator and "Juvenile Diabetes Research Foundation" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Retina-Vitreous Associates" are "Diabetic Macular Edema" (3 trials), "Macular Degeneration" (3 trials), "Choroidal Neovascularization" (2 trials), "Geographic Atrophy" (2 trials) and "Macular Edema" (2 trials). Many other conditions were trialed in "Retina-Vitreous Associates" in a lesser frequency.

Most popular intervention types in "Retina-Vitreous Associates" are "Drug" (8 trials), "Other" (5 trials), "Device" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "KSI-301" (4 trials), "Aflibercept" (3 trials), "Sham Procedure" (3 trials), "Rheopheresis blood filtration" (2 trials) and "ranibizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Retina-Vitreous Associates" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Retina-Vitreous Associates". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in Retina-Vitreous Associates, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Retina-Vitreous Associates, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".